GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
China Reviews Meta’s $2 Billion AI Deal With Manus Amid Technology Control Concerns 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Barclays Invests in Stablecoin Clearing Firm Ubyx to Advance Digital Money Strategy 
Embraer Boosts Aircraft Deliveries in Q4 2025, Signaling Strong Growth Into 2026 
Hyundai Motor Shares Surge on Nvidia Partnership Speculation 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Newmont Goldcorp Expects Lower Q1 2026 Gold Output After Western Australia Bushfire 
Lenovo Unveils AI Cloud Gigafactory With NVIDIA and Launches New AI Platform at CES 2026 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
FDA Limits Regulation of Wearable Devices and Wellness Software, Boosting Health Tech Industry 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
SAN DIEGO, April 05, 2016 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that Charles Theuer, M.D, Ph.D., President and CEO, will present at the 15th Annual Needham Healthcare Conference at 10:40 am EDT on Tuesday, April 12, 2016, at the Westin Grand Central Hotel in New York, NY.
To access a live webcast of the presentation, please visit the “Events and Presentation” section within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes two product candidates: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers and wet AMD through a collaboration with Santen Pharmaceutical Company Ltd., and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 [email protected] Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected]
